Skip to main content

Table 2 PCR-adjusted and unadjusted cure rates of the study participants at day-42 at Dafra health district medical centre, Burkina Faso, 2008–2010

From: In vivo/ex vivo efficacy of artemether–lumefantrine and artesunate–amodiaquine as first-line treatment for uncomplicated falciparum malaria in children: an open label randomized controlled trial in Burkina Faso

Outcome: day 42ALASAQDifference (CI 95%)p-value
Variables
PCR corrected efficacy outcome—no. (%)
Per protocol population (N = 420) n (%)213207
 Adequate clinical and parasitological response194 (91.1)203 (98.1)− 7 (− 11.0 to − 2.7)< 0.0006
 Early treatment failure0 (0.0)0 (0)
 Late clinical failure0 (0.0)0 (0)
 Late parasitological failure19 (8.9)4 (1.9)
 Total number of failure19 (8.9)4 (1.9)
Not corrected for reinfection n (%)
 Adequate clinical and parasitological response106 (49.8)147 (71.0)− 22 (− 31.1 to − 12.9)< 0.0001
 Early treatment failure0 (0)0 (0)
 Late clinical failure32 (15.0)22 (10.6)
 Late parasitological failure75 (35.2)38 (18.4)
 Total number of failure107 (50.2)60 (28.9)
Intent-to-treat population (N = 440)220220
 PCR-adjusted
 Total number of patients n194203  
 Adequate clinical and parasitological response % (95% CI)88.2 (83.2–91.892.3 (87.9–95.2)− 4.1 (− 9.8 to − 1.5)0.148
 PCR-unadjusted
 Total number of patients n106147
 Adequate clinical and parasitological response % (95% CI)48.2 (41.6–54.8)66.8 (60.3–72.8)− 18.6 (− 27.4 to 9.4)< 0.001
  1. AL artemether–lumefantrine, ASAQ artesunate–amodiaquine, CI 95% confident interval, n number, % percentage